New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
10:27 EDTTKMR, NNVC, BCRX, HEBMapp drug used to treat Ebola patients, CNN reports
A drug made by privately held Mapp Biopharmaceutical was used to treat the two Americans who contracted Ebola, CNN reports, citing a source familiar with details of the treatment. The experimental treatment called ZMapp had never been tried before in a human but had showed promise with monkeys, CNN adds. Shares of Tekmira (TKMR), NanoViricides (NNVC), BioCryst (BCRX) and Hemispherx (HEB) are moving higher in early trading after two Americans were flown home with Ebola. Reference Link
News For TKMR;NNVC;BCRX;HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 1, 2014
06:27 EDTBCRXBioCryst volatility flat into CDC confirms first U.S. Ebola case in Texas
Subscribe for More Information
06:19 EDTTKMRTekmira volatility low into CDC confirms first U.S. Ebola case in Texas
Subscribe for More Information
September 30, 2014
18:51 EDTTKMRTekmira surges after hours on first confirmed U.S. Ebola case
Subscribe for More Information
18:36 EDTHEB, TKMR, BCRXOn The Fly: After Hours Movers
Subscribe for More Information
17:58 EDTBCRX, HEB, TKMRCDC confirms first U.S. patient diagnosed with Ebola virus
Subscribe for More Information
17:57 EDTHEBHemispherx up 12% after hours following CDC confirmation of Ebola case in U.S.
17:39 EDTBCRX, TKMRCompanies developing Ebola treatments rise after CDC confirms U.S. Ebola case
Subscribe for More Information
16:47 EDTBCRXBioCryst up 5% after hours following CDC confirmation of Ebola case in U.S.
Subscribe for More Information
16:44 EDTTKMRTekmira up 12% after hours following CDC confirmation of Ebola case in U.S.
September 29, 2014
17:34 EDTNNVCNanoViricides files to delay 10-K
Subscribe for More Information
08:35 EDTHEBHemispherx expands research on potential Ebola treatments
Hemispherx Biopharma announced a widened set of research collaborations designed to develop therapeutic cocktails against Ebola which may potentially overcome the emergence of drug resistance due to Ebola virus mutation. The rapid acquisition of Ebola virus, or EBOV, sequence variation has been recently demonstrated during genomic surveillance of the current Ebola virus disease, or EVD. This observed genomic sequence variation suggests drugs that target specific viral non-variant protein sequences are at risk of mutation mediated activity failure. This complicates significantly the development of EBOV inhibitors in the drug development pipeline, some of which have been highly effective in treating advanced EVD in non-human primates. The two platform drugs of Hemispherx, Alferon N and Ampligen, have certain unique structural attributes and developmental histories which suggest potential incremental value with respect to inclusion in various Ebola therapeutic cocktails under development. First, both drugs have mechanisms of action, which are multifaceted by working thru cellular "molecular cascades" rather than target viral targets whose specificity is vulnerable to mutational change.
September 26, 2014
07:47 EDTTKMR, BCRXEMA to review BioCryst, Sarepta, Tekmira experimental Ebola medicines
Subscribe for More Information
September 25, 2014
06:41 EDTTKMRTekmira volatility flat on wide price movement
Subscribe for More Information
September 23, 2014
06:13 EDTTKMRTekmira to collaborate with international consortium researching Ebola
Subscribe for More Information
September 22, 2014
13:02 EDTTKMRTekmira surges on FDA authorization of TKM-Ebola for emergency use
Subscribe for More Information
12:57 EDTTKMRTekmira up 20% following FDA authorization of TKM-Ebola for emergency use
09:16 EDTTKMRTekmira establishes regulatory framework for emergency use of TKM-Ebola
Subscribe for More Information
08:49 EDTHEBHemispherx announces Alferon LDO primate research peer-reviewed publication
Hemispherx Biopharma announced a peer-reviewed publication entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus by Low Dose Natural Human IFN- Administered to the Buccal Mucosa" in the current issue of Antiviral Research 2014. This publication is a collaborative project conducted at Viroclinics Biosciences BV, Rotterdam, an internationally recognized research facility for the study of influenza viruses. The biohazard laboratories are directed by Prof. Albert D. M. E. Osterhaus, an internationally known virologist specializing in the study of pandemic influenza. Highly pathogenic avian influenza A virus is endemic in wild birds in Asia and the Middle East, causing disease and transmissibility in domestic poultry. Infection of humans with H5N1 is associated with a high mortality rate due to an alveolar destructive primary viral pneumonia frequently expressed clinically as acute respiratory distress syndrome.
September 18, 2014
12:08 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
BioCryst announced that the National Institute of Allergy and Infectious Diseases exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2M increase to the existing development contract. The contract modification and the two additional options exercised represent up to $4M to BioCryst in order to accelerate the development of BCX4430 as a treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. NIAID, part of the National Institutes of Health, granted this five year term contract to BioCryst in September 2013. Approximately $19.9M of funding has been awarded to date under the contract. With this additional award, the BCX4430 development contract has been increased in value to $26.3M, if all options are exercised. This project is funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C.
September 17, 2014
15:02 EDTTKMRCongressman questions why FDA hasn't moved on Ebola drug, The Hill says
Republican Congressman Michael Burgess said he was "bewildered" as to why the FDA continues to have a hold on Tekmira's TKS-Ebloa drug, a treatment for Ebola, according to The Hill. However, Democratic Congresswoman Betty McCollum warned against using Africa as a "testing ground" for drugs that haven't been property screened, the website noted. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use